Drug Type AAV based gene therapy |
Synonyms Targeted SLC3A1/SLC7A9 gene therapy (BridgeBio) |
Target |
Action modulators |
Mechanism SLC3A1 modulators(solute carrier family 3 member 1 modulators), SLC7A9 modulators(solute carrier family 7 member 9 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystinuria | Preclinical | United States | 11 May 2024 |